This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Tildrakizumab for the treatment of psoriasis

Tildrakizumab for the treatment of psoriasis

Read time: 1 mins
Published:1st Jan 2019
Author: Sinclair R, Thirthar Palanivelu V.
Availability: Pay for access, or by subscription
Ref.:Expert Rev Clin Immunol. 2019 Jan;15(1):5-12.
Tildrakizumab for the treatment of psoriasis

Psoriasis is an immune-mediated skin disease amenable to targeted immunotherapy. Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for use in moderate to severe psoriasis.

Areas covered: This article reviews the mechanism of action, pharmacokinetics, safety, tolerability, and clinical efficacy of tildrakizumab, administered subcutaneously every 12 weeks, in treatment of moderate to severe psoriasis.

Expert commentary: In two phase 3 clinical trials, tildrakizumab showed a consistent low occurrence of adverse events, underlining safety and tolerance. The long half-life permits subcutaneous injections every 12 weeks. Seventy eight percent of patients achieved PASI 75 (a > 75% improvement from baseline PASI) at 28 weeks, 58% achieved PASI 90, 29% achieved PASI 100 and 70% achieved a Physician’s Global Assessment score of clear or almost clear. A high proportion of patients maintained PASI response after 2 years of treatment. Tildrakizumab improved Dermatology Life Quality Index, psoriasis-related personal relationship problems and sexual difficulties. Baseline PASI score, PGA, and BMI were not predictive of PASI 90 response at week 12, however achievement of PASI 50 by week 8 was predictive of a PASI 90 response at week 12.

Read abstract on library site Access full article